FLOMAX Drug Patent Profile

Which patents cover Flomax, and when can generic versions of Flomax launch?

Flomax is a drug marketed by Sanofi and is included in one NDA.

The generic ingredient in FLOMAX is tamsulosin hydrochloride. There are thirty-three drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the tamsulosin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Flomax

A generic version of FLOMAX was approved as tamsulosin hydrochloride by IMPAX LABS on March 2^nd, 2010.

Summary for FLOMAX

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for FLOMAX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FLOMAX	Capsules	tamsulosin hydrochloride	0.4 mg	020579	1	2004-12-20

US Patents and Regulatory Information for FLOMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi	FLOMAX	tamsulosin hydrochloride	CAPSULE;ORAL	020579-001	Apr 15, 1997		DISCN	Yes	No

International Patents for FLOMAX

See the table below for patents covering FLOMAX around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	S56110666	PHENYLETHANOLAMINE DERIVATIVE AND ITS PREPARATION
Netherlands	950014
Greece	73827
European Patent Office	0533297	Formulation pharmaceutique à libération contrÔlée (Controlled-release pharmaceutical formulations)

Supplementary Protection Certificates for FLOMAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0034432	SPC/GB96/017: EXPIRE	United Kingdom		SPC/GB96/017: EXPIRES: 20060201
0034432	96C0048	Belgium		PRODUCT NAME: SAQUINAVIR; REGISTRATION NO/DATE: EU/1/96/026/001 19961004

Summary
FLOMAX (tamsulosin) is a generic alpha-1 adrenergic receptor blocker approved for benign prostatic hyperplasia (BPH). Market dynamics, patent expiry, and competitive landscape influence its investment outlook. The drug's core indications and regulatory status shape future growth potential, with key drivers including aging populations and generic competition.

Market Overview and Revenue Landscape
FLOMAX commands a substantial share in the BPH treatment market. As of 2022, its estimated global sales exceeded $1.2 billion. The US market accounts for approximately 60% of sales, driven by high prevalence of BPH in men over 50.

• Patent Status:
  Original patents expired between 2015 and 2017. Post-expiry, generic versions entered the market, resulting in revenue erosion for branded formulations.

• Key Competitors:
  Other alpha-1 blockers like doxazosin and terazosin gather market share. Novel agents and combination therapies (e.g., alpha blockers with PDE5 inhibitors) challenge FLOMAX’s dominance.

• Pricing Dynamics:
  Generic competition has led to a significant price decline. Branded versions in the US previously averaged about $7 per pill; generics now sell under $4 per pill.

Regulatory and Patent Landscape

• Original Patents:
  Filed in the 1990s, expired in the late 2010s. The expiration opened the market for generics.

• Patent Litigation and Exclusivity:
  Some formulations held secondary patents until 2020, delaying generic entries. Patent challenges from competitors led to patent terminations in several jurisdictions.

• Regulatory Approvals:
  FDA approval for generic tamsulosin was granted in 2003, following generic drug approvals in Europe in 2004. No recent innovations or new formulations have received regulatory approval.

Fundamental Drivers and Risks

• Aging Demographics:
  Increasing male population over 50 boosts BPH prevalence. US Census forecasts indicate men over 50 will reach 150 million by 2030, supporting sustained medication demand.

• Market Penetration:
  Penetration rates in the US are approximately 40-50%. Growth depends on increased diagnosis rates, healthcare provider prescribing habits, and patient acceptance.

• Pricing and Reimbursement Policies:
  US Medicare and private insurers' preferences for lower-cost generics exert downward pressure on prices.

• Innovation and Line Extensions:
  No significant improvements or combination therapies based on tamsulosin have been approved recently, constraining growth.

• Regulatory Risks:
  Future patent litigations or regulatory barriers could influence profitability.

Investment Prospects and Strategies

• Short-term Outlook:
  Revenue will decline as generics dominate; however, stable cash flows remain due to broad prescribing patterns.

• Long-term View:
  Limited innovation constrains growth. Companies with existing patents on formulations or delivery methods may shield revenues temporarily.

• Partnerships and M&A:
  Firms exploring combination therapies or novel BPH agents could acquire or partner with generic manufacturers to diversify portfolios.

Summary of Key Indicators	Indicator	Status	Comments
Patent Expiry	2015-2017	Major patent loss, leading to generic entry
Estimated Global Sales	>$1.2 billion (2022)	Significant revenue, rapidly declining post-generic
Number of Competitors	Several	Doxazosin, terazosin, and new entrants
Market Penetration (US)	40-50%	Growth dependent on diagnosis and prescribing rates

Key Takeaways

• FLOMAX faces a declining branded market but retains a substantial volume of prescriptions globally.
• Patent expirations led to generics capturing the majority of revenue, with prices already suppressed.
• Market growth hinges on demographic trends, with limited potential for innovative breakthroughs.
• Competitive pressures and reimbursement policies favor lower-cost generics, constraining revenue expansion.
• Companies with diversified portfolios or pipeline assets are better positioned to offset FLOMAX’s downward trajectory.

FAQs

Last updated: February 3, 2026

1. What is the primary market for FLOMAX?
   The US dominates, accounting for about 60% of sales, driven by high BPH prevalence and prescription rates.

2. How does patent expiry affect FLOMAX's market?
   Expiry led to generic entries, decreasing prices and reducing revenue for branded formulations.

3. Are there any new formulations or uses for FLOMAX?
   No; recent patent expirations and lack of innovation hinder new growth avenues.

4. What regulatory factors influence FLOMAX?
   Patent challenges and generic approvals are primary regulatory considerations; no recent new drug approvals are noted.

5. What is the outlook for investors interested in FLOMAX?
   The outlook is bearish in terms of revenue growth; focus should be on legacy revenue streams or companies with diversified pipelines.

Citations
[1] IQVIA. "Smartitrate Database."
[2] US Patent and Trademark Office. "Patent Status and Expirations."
[3] FDA. "Drug Approvals and Regulatory Decisions."
[4] MarketWatch. "Global Benign Prostatic Hyperplasia Market Analysis."
[5] Statista. "BPH Prevalence and Demographics."